www.excemed.org
IMPROVING THE PATIENT’S LIFE THROUGH
MEDICAL EDUCATION
Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy
2
What is to be considered Treatment Failure in MS?
Claudio Gasperini Centro di Riferimento Regionale
per la Sclerosi Multipla Ospedale S Camillo-Forlanini di Roma
3
Background
• Several therapeutic opportunities for MS patients
• Current MS treatments reduce frequency of relapses,
disability progression and disease activity (as measured
by MRI).
• Response varies among patients. Difficult to assess
• How to switch after suboptimal response?
4
Assessment of treatment response
Disease progression
Disability
Relapses
MRI activity
Focal inflammation
(relapses / MRI lesions)
Diffuse damage accumulation
(neurodegeneration / failure of repair; disability / atrophy)
5
No evidence of
disease activity (NEDA) Slowing disability
progression Symptom management
Treatment goals in MS: paradigm shifts driven by emerging therapies
The growing availability of drugs active against MS over years leads to greater expectations
modified from Ransohoff RM et al. Nat Rev Neurol 2015
Recovery of function
6
NEDA at 1 year 34% for PegInterferon (ADVANCE)
47% for Natalizumab (AFFIRM)
39% for Daclizumab (SELECT)
NEDA at 2 years 37% for Natalizumab (AFFIRM)
39% for Alemtuzumab (CARE-MS I)
32% for Alemtuzumab (CARE-MS II)
46% for Cladribine (CLARITY)
28% for Dimethyl Fumarate (DEFINE)
33% for Fingolimod (FREEDOMS)
18% and 23% for Teriflunomide 7mg and 14mg (TEMSO)
NEDA at 3 years 19% for Glatiramer Acetate (CombiRx)
21% for IFN-B 1a (CombiRx)
33% for Glatiramer Acetate+IFNB1a (CombiRx)
NEDA-4: 20% for Fingolimod (FREEDOMS+FREEDOMS II)
NEDA – Clinical trial data
7
NEDA
NEDA is an important therapeutic goal in MS care.
Data from clinical trials show that NEDA is a very interesting outcome measure, showing clear difference between placebo and treated arms. However, only a minor portion of patients (range 18-46%) are NEDA in the short term after treatment with current DMT’s
In clinical settings, NEDA is difficult to sustain in the long term. Should we aim for “minimal evidence of disease activity” (MEDA)?
The definition of NEDA should evolve as new metrics are adopted into clinical practice (e.g,T25FW, SDMT, brain atrophy, etc.)
8 8
Defining treatment response is challenging: the proportion non-
responders varies depending on definition
• Patients (N = 393) treated with IFN β for ≥ 2 years.
Rίo J, et al. Nat Rev Neurol 2009; 5:553–560. Non-responder definitions % non-responders Hazard ratio
A ≥ 1 EDSS point confirmed at 6 months 18 39.623
B Presence of any relapse 45 6.366
C ≥ 2 relapses 20 4.562
D A decrease in relapse rate of < 30% compared with the 2 years before therapy 16 4.830
E A decrease in relapse rate of < 50% compared with the 2 years before therapy 20 4.009
F No decrease in or identical relapse rate compared with the 2 years before therapy
15 4.620
G Definition A or B 49 10.028
H Definition A or E 30 19.869
I Definition A and B 13 41.143
J Definition A and E 7 24.544
Patients (N = 393) treated with IFN β for ≥ 2 years. Rίo J, et al. Nat Rev Neurol 2009; 5:553–560.
242 RRMS patients with IFN beta-1a treatment (follow-up 4.3 2.3 anni)
Pozzilli et al., Neurol Sci 2005
MRI and identification of responders
Definition of not responder:
2 or more clinical relapses during follow-up (35% dei pazienti)
OR 3.6, IC 95% 1.3-10.2 OR 2.8, IC 95% 1.1-7.3
Responders
Poor responders
Poor Response defined as an increase of at least 1 point of EDSS confirmed at 6 months
13
0-1 year 0-2 years PTE, % (95%CI)
MRI lesions Progression 63 (20-215)
Relapses Progression 61 (15-234)
MRI lesions and relapses
Progression 100 (32-311)
PRISMS study (scIFN-1a)
MRI+relapses -> disability (INDIVIDUAL LEVEL)
P=0.038
p=0.038
IFN
Placebo
14
16
0 (low risk)
1
2-3 (high risk)
Training set (PRISMS)
0
1
2-3
Validation set (Barcelona)
17
0
1
2-3
Training set (PRISMS)
?
0
2-3
No relapse and =2 new T2 lesions in month 12-
18
18
19
Assessing response to Interferon in a large multicentre clinical
dataset of patients with multiple sclerosis
MP Sormani, C Gasperini, Rocca M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M,
Gallo A, Kappos L, Marrosu M, Martinelli V, Montalban X, Prosperini L, Rovira A, Sprenger T, Stromillo
ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Pozzilli C, Comi G, N De Stefano, MD on behalf of
the MAGNIMS study group.
Conclusion: Results of the study suggest that substantial MRI activity, better if in combination with
clinical relapses, is needed during the first year of treatment with Interferon to significantly increase the
risk of disability worsening in the short-term.
Accepted Neurology
20 20
610
568
233 120
106
91
88
32
27
14
MAGNIMS Project - Participating Centers
21
Center Patient # %
Rome 610 32.3
Milan 568 30.1
Barcelona 233 12.3
Bari 120 6.3
Cagliari 106 5.6
Siena 91 4.8
Verona 88 4.7
Graz 32 1.7
Napoli 27 1.4
Basel 14 .7
Total 1890 100
Center Patient # %
Rome 610 32.3
Milan 568 30.1
Barcelona 233 12.3
Other MAGNIMS 479 25.3
Total 1890 100
In the statistical analysis, centers
with small sample size (
22 22
Disability progression across centers
p
23 23
Optimized score
Variables HR (95%CI) p
NewT2 lesions=0 Ref
NewT2 lesions=1 0.93 (0.62-1.4) 0.73
NewT2 lesions=2 1.09 (0.71-1.68) 0.68
NewT2 lesions=3 1.65 (1.01-2.70) 0.04
NewT2 lesions=4 2.26 (1.29-3.97)
24 24
MAGNIMS Score
Score 0: 0 Relapses and 0-2 New T2 Lesions Score 1: 0 Relapses and 3+ New T2 Lesions, or 1 Relapses and 0-2 New T2 Lesions Score 2: 2+ Relapses or 1 Relapse and 3+ New T2 Lesions
25 25
26
Summary
• With a suboptimal response on first-line drugs, a
change in management strategy needs to be
considered
• Combination of both clinical and MRI measures is the
best way to assess treatment response
• Integrated scoring systems incorporating clinical and
MRI measures of disease activity could be useful for a
personalized approach to treatment
27
Thank you for your kind attention !!!
Tintore et al Neurology 2010 Sombekke et al Neurology 2013
Relevance of lesion location